ES2210268T3 - Procedimiento para potenciar respuestas inmunes y composiciones correspondientes. - Google Patents

Procedimiento para potenciar respuestas inmunes y composiciones correspondientes.

Info

Publication number
ES2210268T3
ES2210268T3 ES95112851T ES95112851T ES2210268T3 ES 2210268 T3 ES2210268 T3 ES 2210268T3 ES 95112851 T ES95112851 T ES 95112851T ES 95112851 T ES95112851 T ES 95112851T ES 2210268 T3 ES2210268 T3 ES 2210268T3
Authority
ES
Spain
Prior art keywords
microcapsules
antigen
biocompatible
excipient
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95112851T
Other languages
English (en)
Spanish (es)
Inventor
Thomas T. Tice
John H. Eldridge
Richard M. Gilley
Jay K. Stass
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Southern Research Institute
Original Assignee
UAB Research Foundation
Southern Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22617981&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2210268(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UAB Research Foundation, Southern Research Institute filed Critical UAB Research Foundation
Application granted granted Critical
Publication of ES2210268T3 publication Critical patent/ES2210268T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y10T428/2985—Solid-walled microcapsule from synthetic polymer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2989—Microcapsule with solid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Electrotherapy Devices (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Vending Machines For Individual Products (AREA)
ES95112851T 1988-03-18 1989-03-20 Procedimiento para potenciar respuestas inmunes y composiciones correspondientes. Expired - Lifetime ES2210268T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/169,973 US5075109A (en) 1986-10-24 1988-03-18 Method of potentiating an immune response
US169973 1988-03-18

Publications (1)

Publication Number Publication Date
ES2210268T3 true ES2210268T3 (es) 2004-07-01

Family

ID=22617981

Family Applications (2)

Application Number Title Priority Date Filing Date
ES95112851T Expired - Lifetime ES2210268T3 (es) 1988-03-18 1989-03-20 Procedimiento para potenciar respuestas inmunes y composiciones correspondientes.
ES89302746T Expired - Lifetime ES2088890T3 (es) 1988-03-18 1989-03-20 Metodo de potenciacion de una respuesta inmune y composiciones para el mismo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES89302746T Expired - Lifetime ES2088890T3 (es) 1988-03-18 1989-03-20 Metodo de potenciacion de una respuesta inmune y composiciones para el mismo.

Country Status (20)

Country Link
US (1) US5075109A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (3) EP1181929A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2521827B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR0126823B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (3) CN1211080C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (2) ATE140386T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU633483B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1340692C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE68926828T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK175851B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2210268T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3020569T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK38897A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE83868B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL89602A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN169330B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ228376A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (3) RU2250102C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1989008449A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA892103B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (651)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US6217911B1 (en) 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
US6410056B1 (en) 1984-03-16 2002-06-25 The United States Of America As Represented By The Secretary Of The Army Chemotherapeutic treatment of bacterial infections with an antibiotic encapsulated within a biodegradable polymeric matrix
USRE40786E1 (en) 1984-03-16 2009-06-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres
US5693343A (en) 1984-03-16 1997-12-02 The United States Of America As Represented By The Secretary Of The Army Microparticle carriers of maximal uptake capacity by both M cells and non-M cells
NZ217821A (en) * 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US5807832A (en) * 1987-06-09 1998-09-15 Biotech Australia Pty Limited Oral delivery of biologically active substances bound to vitamin B12
US5116612A (en) * 1987-06-23 1992-05-26 Allergy Immuno Technologies, Inc. Immunotherapy agents for treatment of IgE mediated allergies
US5236705A (en) * 1989-01-20 1993-08-17 The University Of Melbourne Fibrinolysis
AU639903B2 (en) * 1989-01-20 1993-08-12 University Of Melbourne, The Fibrinolysis
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
WO1990013361A1 (en) * 1989-05-04 1990-11-15 Southern Research Institute Improved encapsulation process and products therefrom
US6126945A (en) * 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
DK546289D0 (da) * 1989-11-02 1989-11-02 Danochemo As Carotenoidpulvere
AU642932B2 (en) * 1989-11-06 1993-11-04 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
WO1991016073A1 (en) * 1990-04-24 1991-10-31 The University Of Newcastle Research Associates Limited Oral vaccine comprising antigen surface-associated with red blood cells
US5882649A (en) * 1990-04-24 1999-03-16 Flustat Pty. Ltd. Oral vaccine comprising antigen surface-associated with red blood cells
US5780012A (en) * 1990-06-21 1998-07-14 Huland; Edith Method for reducing lung afflictions by inhalation of cytokine solutions
EP0462305B1 (de) * 1990-06-21 1994-11-02 Huland, Edith, Dr. Dr. Verwendung zytokinhaltiger Aerosole und zytokinhaltige Aerosole selbst
ES2108111T3 (es) * 1991-04-02 1997-12-16 Biotech Australia Pty Ltd Sistemas de suministro oral de microparticulas.
WO1992019263A1 (en) 1991-04-24 1992-11-12 The United States Of America, As Represented By The Secretary Of The Army Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US5283066A (en) * 1992-02-19 1994-02-01 Development Center For Biotechnology Method of stimulating an immune response by using a hapten
US5352461A (en) * 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
US6197346B1 (en) 1992-04-24 2001-03-06 Brown Universtiy Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US6235313B1 (en) 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US5922340A (en) * 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
US5700485A (en) * 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
PT659073E (pt) * 1992-09-10 2002-06-28 Childrens Medical Center Matrizes polimericas biodegradaveis para entrega sustentada de agentes anestesicos locais
WO1994007469A1 (en) * 1992-09-25 1994-04-14 Dynagen, Inc. An immunobooster for delayed release of immunogen
WO1994010980A1 (en) * 1992-11-16 1994-05-26 Corporation Of Mercer University Compositions using microencapsulated neutralizing antibodies
ES2095001T5 (es) * 1992-12-22 2001-03-16 Univ Cincinnati Una composicion terapeutica administrable oralmente y su metodo de obtencion.
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6939546B2 (en) 1993-05-21 2005-09-06 The United States Of America As Represented By The Secretary Of The Army Model for testing immunogenicity of peptides
US5603960A (en) * 1993-05-25 1997-02-18 O'hagan; Derek T. Preparation of microparticles and method of immunization
US5562909A (en) * 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
US6004534A (en) * 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
WO1995003035A1 (en) * 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Polymerized liposomes with enhanced stability for oral delivery
DK0724432T3 (da) * 1993-10-22 2003-01-27 Genentech Inc Fremgangsmåder og præparater til mikroindkapsling af antigener til brug som vacciner
EP0724431B1 (en) * 1993-10-22 2002-09-11 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
CA2172508C (en) * 1993-10-22 2005-08-23 Jeffrey L. Cleland Method for preparing microspheres comprising a fluidized bed drying step
US6080429A (en) * 1993-10-25 2000-06-27 Genentech, Inc. Method for drying microspheres
US5643605A (en) * 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
US6913767B1 (en) 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
SI0729357T1 (en) 1993-11-19 2005-06-30 Janssen Pharmaceutica N.V. Microencapsulated 1,2-benzazoles
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
US6531156B1 (en) 1994-04-15 2003-03-11 Temple University Aqueous solven encapsulation method, apparatus and microcapsules
US6013268A (en) 1994-04-22 2000-01-11 Corixa Corporation Methods for enhancement of protective immune responses
US5876735A (en) * 1994-04-22 1999-03-02 Corixa Corporation Methods for enhancement of protective immune responses
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US6855331B2 (en) 1994-05-16 2005-02-15 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US5571531A (en) * 1994-05-18 1996-11-05 Mcmaster University Microparticle delivery system with a functionalized silicone bonded to the matrix
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US5696087A (en) * 1994-12-01 1997-12-09 Oklahoma Medical Research Foundation Method and compositions for reducing cholesterol absorption
US5821226A (en) * 1994-12-01 1998-10-13 Oklahoma Medical Research Foundation BAL C-tail drug delivery molecules
US5681819A (en) * 1994-12-01 1997-10-28 Oklahoma Medical Research Foundation Method and compositions for reducing cholesterol absorption
US7033608B1 (en) 1995-05-22 2006-04-25 The United States Of America As Represented By The Secretary Of The Army “Burst-free” sustained release poly-(lactide/glycolide) microspheres
US6902743B1 (en) 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
CA2195119C (en) 1995-06-09 2001-09-11 Mark Chasin Formulations and methods for providing prolonged local anesthesia
EP0840623B1 (en) * 1995-07-21 2007-07-18 Brown University Research Foundation Compositions for gene therapy comprising nucleic acid loaded polymeric microparticles
US6248720B1 (en) 1996-07-03 2001-06-19 Brown University Research Foundation Method for gene therapy using nucleic acid loaded polymeric microparticles
US6143211A (en) 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
HU225979B1 (en) 1995-09-01 2008-02-28 Corixa Corp Compounds and methods for immunotherapy and diagnosis of tuberculosis
EP0862419B2 (en) † 1995-11-09 2010-11-17 Microbiological Research Authority Microencapsulated dna for vaccination and gene therapy
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
US5985312A (en) * 1996-01-26 1999-11-16 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
US6342218B1 (en) 1997-02-14 2002-01-29 Oklahoma Medical Research Foundation Method for treatment of SLE
US6117449A (en) * 1996-03-22 2000-09-12 Bio-Sphere Technology, Inc. Method for inducing a systemic immune response to a hepatitis antigen
US6207185B1 (en) 1996-03-22 2001-03-27 Bio-Sphere Technology Method for inducing a systemic immune response to an HIV antigen
US6015576A (en) * 1997-08-29 2000-01-18 Bio-Sphere Technology, Inc. Method for inducing a systemic immune response to an antigen
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US20020052310A1 (en) 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
JPH11511763A (ja) 1996-06-24 1999-10-12 ユーロ―セルティーク，エス．エイ． 安全な局所麻酔の提供方法
US5955096A (en) * 1996-06-25 1999-09-21 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
US6344202B1 (en) * 1996-07-12 2002-02-05 University Of Manitoba DNA immunization against chlaymdia infection
US5980948A (en) * 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
US6046187A (en) 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
DK1005374T3 (da) * 1997-01-22 2007-08-20 Mgi Pharma Biolog Inc Mikropartikler til fremföring af nukleinsyre
EP0981624A2 (en) 1997-02-12 2000-03-01 Corixa Corporation $i(LEISHMANIA) ANTIGENS FOR USE IN THE THERAPY AND DIAGNOSIS OF LEISHMANIASIS
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1998043630A1 (en) 1997-04-02 1998-10-08 Brigham And Women's Hospital, Inc. Means of ascertaining an individual's risk profile for atherosclerotic disease
ZA982968B (en) 1997-04-09 1998-10-27 Corixa Corp Compositions and methods for the treatment and diagnosis of breast cancer
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
KR100367144B1 (ko) 1997-07-02 2003-01-14 유로-셀티크 소시에떼 아노뉨 관절과 체강(ｂｏｄｙ ｓｐａｃｅ)내에서 연장된 마취
US6312731B1 (en) * 1997-08-29 2001-11-06 Southern Research Institute Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof
EP1579851A3 (en) * 1997-08-29 2009-09-02 Corixa Corporation Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of use thereof
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6197229B1 (en) * 1997-12-12 2001-03-06 Massachusetts Institute Of Technology Method for high supercoiled DNA content microspheres
ES2175668T3 (es) * 1997-12-16 2002-11-16 Chiron Corp Uso de microparticulas combinadas con emulsiones de aceite en agua submicronicas.
US7393630B2 (en) 1997-12-16 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Use of microparticles combined with submicron oil-in-water emulsions
EP1042360A2 (en) 1997-12-24 2000-10-11 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
EP2003201A3 (en) 1998-03-18 2008-12-31 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
PL202844B1 (pl) 1998-04-07 2009-07-31 Corixa Corp Immunogeniczny polipeptyd, polinukleotyd, polipeptyd, kompozycja farmaceutyczna, wektor ekspresji, kompozycja szczepionki, polipeptyd do stosowania w leczeniu lub zapobieganiu infekcjom Mycobacterium tuberculosis, polinukleotyd do stosowania w leczeniu lub zapobieganiu infekcjom Mycobacterium tuberculosis i sposób wytwarzania polipeptydu
AU3555599A (en) 1998-04-13 1999-11-01 Luminex Corporation Liquid labeling with fluorescent microparticles
SE9801288D0 (sv) 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
AU761899B2 (en) 1998-05-22 2003-06-12 Ottawa Health Research Institute Methods and products for inducing mucosal immunity
WO1999065531A1 (en) 1998-06-18 1999-12-23 Johns Hopkins University School Of Medicine Polymers for delivery of nucleic acids
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
TR200100373T2 (tr) 1998-08-07 2001-09-21 University Of Washington İmünolojik uçuk virüsü antijenleri ve bunların kullanım yöntemleri
US6264991B1 (en) 1998-08-18 2001-07-24 Southern Research Institute Compositions and methods for treating intracellular infections
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US7087236B1 (en) 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
ATE452651T1 (de) 1998-09-01 2010-01-15 Merrion Res Iii Ltd Orale impfstoff-zusammensetzung
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
FR2786098B1 (fr) 1998-11-20 2003-05-30 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
HUP0400719A3 (en) 1998-12-08 2010-08-30 Corixa Corp Compounds and methods for treatment and diagnosis of chlamydial infection
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
EP1141017B1 (en) 1998-12-30 2008-09-10 Beth Israel Deaconess Medical Center, Inc. Characterization of the soc/crac calcium channel protein family
US6395714B1 (en) 1999-02-24 2002-05-28 Aventis Pasteur Limited Expressing gp140 fragment of primary HIV-1 isolate
IL145731A0 (en) 1999-04-02 2002-07-25 Corixa Corp A polypetide containing an immunogenic portion of a breast tumor protein and pharmaceutical compositions containing the same
US20050158856A1 (en) * 1999-04-20 2005-07-21 Edelson Richard L. Methods for producing functional antigen presenting dendritic cells using biodegradable microparticles for delivery of antigenic materials
US6521431B1 (en) * 1999-06-22 2003-02-18 Access Pharmaceuticals, Inc. Biodegradable cross-linkers having a polyacid connected to reactive groups for cross-linking polymer filaments
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
JP4210454B2 (ja) * 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
US20020009466A1 (en) * 1999-08-31 2002-01-24 David J. Brayden Oral vaccine compositions
AU7574700A (en) 1999-09-03 2001-04-10 Brigham And Women's Hospital Methods and compositions for treatment of inflammatory disease using cadherin-11modulating agents
US6811783B1 (en) 1999-09-07 2004-11-02 Aventis Pasteur Limited Immunogenic compositions for protection against chlamydial infection
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US20050037086A1 (en) * 1999-11-19 2005-02-17 Zycos Inc., A Delaware Corporation Continuous-flow method for preparing microparticles
FR2801226B1 (fr) 1999-11-23 2002-01-25 Flamel Tech Sa Suspension colloidale de particules submicroniques de vectorisation de principes actifs et son mode de preparation
PT1265915E (pt) 2000-02-23 2011-02-07 Glaxosmithkline Biolog Sa Novos compostos
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
EP1328261A2 (en) * 2000-04-12 2003-07-23 Minerva Biotechnologies Corporation Treatment of neurodegenerative disease
WO2001081379A2 (en) 2000-04-21 2001-11-01 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
DE60112073T2 (de) 2000-05-12 2006-04-20 Pharmacia & Upjohn Co. Llc, Kalamazoo Impfstoffzusammensetzung und verfahren zur herstellung derselben sowie verfahren zur impfung von wirbeltieren
AU2001268159B2 (en) * 2000-06-02 2005-09-15 Eisai Inc. Delivery systems for bioactive agents
FR2814952B1 (fr) 2000-10-06 2004-01-02 Flamel Tech Sa Suspension colloidale de particules submicromiques de vectorisation de principes actifs et leur mode de preparation
EP2133100B1 (en) 2000-06-20 2011-10-05 Corixa Corporation MTB32A Antigen of mycobacterium tuberculosis with inactivated active site and fusion proteins thereof
AU2001270134B2 (en) 2000-06-22 2006-06-15 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
AR029540A1 (es) 2000-06-28 2003-07-02 Corixa Corp COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN
US6565888B1 (en) 2000-08-23 2003-05-20 Alkermes Controlled Therapeutics, Inc. Methods and compositions for the targeted delivery of biologically active agents
US6797704B2 (en) 2000-10-06 2004-09-28 The Johns Hopkins University Systemic delivery of compounds through non-invasive bladder administration
US7374782B2 (en) 2000-10-27 2008-05-20 Baxter International Inc. Production of microspheres
WO2002056022A2 (en) 2000-11-27 2002-07-18 Minerva Biotechnologies Corp Diagnostics, drug screening and treatment for cancer
WO2005019269A2 (en) 2002-11-27 2005-03-03 Minerva Biotechnologies Corporation Techniques and compositions for the diagnosis and treatment of cancer (muc1)
ATE398175T1 (de) * 2000-12-08 2008-07-15 Coley Pharmaceuticals Gmbh Cpg-artige nukleinsäuren und verfahren zu ihrer verwendung
CA2433335C (en) 2000-12-29 2010-04-20 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
US20030125236A1 (en) * 2000-12-29 2003-07-03 Advenced Inhalation Research, Inc. Particles for inhalation having rapid release properties
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
KR100927261B1 (ko) 2001-01-17 2009-11-18 트루비온 파마슈티칼스, 인코포레이티드 결합 도메인-면역글로불린 융합 단백질
US7618939B2 (en) * 2001-02-15 2009-11-17 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
EP1988097A1 (en) 2001-05-09 2008-11-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030108565A1 (en) 2001-07-10 2003-06-12 Johnson Mark E. Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
CA2456806C (en) * 2001-08-08 2011-10-18 Brown University Research Foundation Methods for micronization of hydrophobic drugs
US20030064033A1 (en) * 2001-08-16 2003-04-03 Brown Larry R. Propellant-based microparticle formulations
EP1455593B1 (en) 2001-10-06 2013-07-24 Merial Limited Methods and compositions for promoting growth and innate immunity in young animals
HK1080090B (zh) 2001-10-10 2012-12-14 诺和诺德公司 肽的重构和糖缀合的方法
AU2002340662B2 (en) * 2001-11-07 2008-07-03 Tekmira Pharmaceuticals Corporation Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
WO2003072016A2 (en) 2001-11-19 2003-09-04 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
DK1455755T3 (da) 2001-11-20 2013-07-15 Civitas Therapeutics Inc Forbedrede partikelsammensætning til levering i lunge
AU2002346472A1 (en) * 2001-11-20 2003-06-10 Advanced Inhalation Research, Inc. Particulate compositions for improving solubility of poorly soluble agents
AU2002360549A1 (en) * 2001-12-10 2003-06-23 Spherics, Inc. Methods and products useful in the formation and isolation of microparticles
KR101124363B1 (ko) 2001-12-11 2012-03-21 앵스티띠 나셔날 드 라 쌍뜨 에 드 라 르셰르슈 메디깔 면역조절곤란증을 포함하는 질병을 치료하기 위한 그람양성균 제제
EP1581119B1 (en) 2001-12-17 2013-01-30 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
ES2364636T3 (es) 2001-12-19 2011-09-08 Novartis Ag Administración pulmonar de aminoglucósidos.
CA2477604A1 (en) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
WO2003086280A2 (en) 2002-04-04 2003-10-23 Coley Pharmaceutical Gmbh Immunostimulatory g,u-containing oligoribonucleotides
BRPI0309142C1 (pt) 2002-04-09 2021-05-25 Flamel Ireland Ltd suspensão de microcápsulas em uma fase líquida aquosa, que permite a liberação modificada de pelo menos um princípio ativo com exclusão da amoxicilina e que é destinada a ser administrada por via oral
AU2003234407B2 (en) 2002-05-09 2008-12-18 The Brigham And Women's Hospital, Inc. 1L1RL-1 as a cardiovascular disease marker and therapeutic target
US20040009944A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Methylated immunostimulatory oligonucleotides and methods of using the same
US20040013649A1 (en) * 2002-05-10 2004-01-22 Inex Pharmaceuticals Corporation Cancer vaccines and methods of using the same
FR2840614B1 (fr) 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
EP2865386B1 (en) 2002-07-18 2017-07-05 University of Washington Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments
WO2004035028A1 (fr) * 2002-10-17 2004-04-29 Gosudarstvenny Nauchny Tsentr Virusologii I Biotekhnologii 'vektor' Procede de production d'une forme microencapsulee d'un vaccin viral vivant
JP2006503914A (ja) * 2002-10-21 2006-02-02 エムジーアイ ファーマ バイオロジックス インコーポレイテッド ヒトパピローマウイルス媒介性疾患を治療するための組成物および方法
SI2241325T1 (sl) 2002-10-29 2012-05-31 Coley Pharm Group Inc Uporaba CPG oligonukleotidov pri zdravljenju okužbe z virusom hepatitisa C
NZ542267A (en) 2003-02-11 2008-12-24 Shire Human Genetic Therapies Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
ES2439580T5 (en) 2003-02-28 2025-01-23 Univ Johns Hopkins T cell regulation
EP1599474B1 (en) * 2003-03-04 2013-04-24 California Institute Of Technology Heterocyclic oligomeric compounds for DNA recognition
EP1608688B1 (en) 2003-03-14 2013-02-27 BioGeneriX AG Branched water-soluble polymers and their conjugates
EP2338333B1 (en) 2003-04-09 2017-09-06 ratiopharm GmbH Glycopegylation methods and proteins/peptides produced by the methods
EP1651207A4 (en) 2003-06-12 2008-10-01 Univ Colorado SYSTEMS AND METHODS FOR THE TREATMENT OF HUMAN INFLAMMATORY AND PROLIFERATIVE DISEASES AND INJURIES USING INHIBITORS OF FATTY ACID METABOLISM AND / OR GLYCOLYTIC INHIBITORS
EP1636270B1 (en) 2003-06-16 2016-07-20 UCB Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
DE10329087B4 (de) * 2003-06-27 2014-02-13 Biomedical International R + D Gmbh Antigenhaltige Mikrosphären zur Allergietherapie
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
US20050147687A1 (en) * 2003-07-18 2005-07-07 Julia Rashba-Step Methods for fabrication, uses and compositions of small spherical particles of AAT prepared by controlled phase separation
US20070092452A1 (en) * 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
EP1646354A4 (en) * 2003-07-22 2010-03-17 Baxter Int SMALL SPHERICAL PARTICLES OF LOW MOLECULAR WEIGHT MOLECULES AND PROCESSES FOR THEIR PREPARATION AND USE
US7663017B2 (en) 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
JP2007502991A (ja) 2003-08-20 2007-02-15 バイオサイト インコーポレイテッド 生物活性ナトリウム利尿ペプチドを測定するための、およびその治療可能性を向上させるための方法および組成物
US20060173171A1 (en) * 2003-08-26 2006-08-03 Bamdad Cynthia C Techniques and compositions for diagnosis and treatment of cancer (muci)
EP1675614A2 (en) * 2003-10-11 2006-07-05 Inex Pharmaceuticals Corp. Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
AU2004299457B2 (en) 2003-12-12 2011-03-24 Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services A human cytotoxic T-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of MUC-1
EP2248895B8 (en) 2003-12-19 2016-09-21 Autotelic LLC Combination therapy associating a TGF-beta antagonist with a chemotherapeutic agent
US7452730B2 (en) * 2004-01-16 2008-11-18 California Institute Of Technology DNA-binding polymers
JP5650367B2 (ja) * 2004-02-27 2015-01-07 アンティセンス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物
EP1568383A3 (en) 2004-02-27 2005-11-16 Antisense Pharma GmbH Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
US7063151B2 (en) * 2004-03-05 2006-06-20 Halliburton Energy Services, Inc. Methods of preparing and using coated particulates
ES2738112T3 (es) 2004-04-21 2020-01-20 Brigham & Womens Hospital Inc Péptidos de fijación a la poli-N-acetil glucosamina (PNAG/dPNAG) y procedimientos para el uso de los mismos
US20050239723A1 (en) * 2004-04-27 2005-10-27 Amin Avinash N Compositions and methods useful for treatment of acne
DK2072040T3 (da) 2004-05-12 2013-07-29 Baxter Healthcare Sa Terapeutisk anvendelse af nukleinsyremikrokugler
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
JP2007537288A (ja) 2004-05-12 2007-12-20 バクスター インターナショナル インコーポレイテッド オリゴヌクレオチド含有マイクロスフェア、１型糖尿病を処置する医薬の製造のための、その使用
AU2005244840C1 (en) * 2004-05-12 2012-05-10 Baxter Healthcare S.A. Microspheres comprising protein and showing injectability at high concentrations of said agent
WO2006031264A2 (en) 2004-05-25 2006-03-23 Oregon Health And Science University Siv and hiv vaccination using rhcmv- and hcmv-based vaccine vectors
US20060264411A1 (en) * 2005-05-20 2006-11-23 Eldridge Gary R Control of biofilm formation
US20060014285A1 (en) * 2004-07-14 2006-01-19 Eldridge Gary R Methods and compositions for inhibiting biofilms
US7604978B2 (en) 2004-07-14 2009-10-20 Sequoia Sciences, Inc. Inhibition of biofilm formation
DE602005023629D1 (de) 2004-07-14 2010-10-28 Univ California Biomarker für den frühzeitigen nachweis von ovarialkarzinom
JP5230865B2 (ja) 2004-07-15 2013-07-10 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ結合性化合物
SG190665A1 (en) 2004-07-30 2013-06-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
US9132116B2 (en) 2004-08-02 2015-09-15 Willowcroft Pharm Inc. Mast cell stabilizers to prevent or treat laminitis
CN101106997A (zh) 2004-08-17 2008-01-16 约翰·霍普金斯大学 Pde5抑制剂组合物及治疗心脏病征候的方法
WO2006028967A2 (en) * 2004-09-02 2006-03-16 Yale University Regulation of oncogenes by micrornas
WO2007053135A1 (en) * 2004-09-14 2007-05-10 Minerva Biotechnologies Corporation Methods for diagnosis and treatment of cancer
US7612045B2 (en) 2004-09-14 2009-11-03 Sequoia Sciences, Inc. Compounds, compositions and methods for controlling biofilms and bacterial infections
RU2419628C2 (ru) * 2004-09-22 2011-05-27 ГлаксоСмитКлайн Байолоджикалз с.а. Иммуногенная композиция для применения в вакцинации против стафилококков
US20080138847A1 (en) * 2004-09-23 2008-06-12 Yigong Shi Bcl-2 family member and BH-3 only proteins for use in development of peptidomimetics
EP2343553A1 (en) 2004-10-06 2011-07-13 The Brigham and Women's Hospital Relevance of achieved levels of markers of systemic inflammation following treatment
EP1797173B1 (en) 2004-10-08 2014-05-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Modulation of replicative fitness by using less frequently used synonymous codons
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
EP2295036A2 (en) 2004-12-10 2011-03-16 Talima Therapeutics, Inc. Liquid compositions and methods for treating conditions of the nail unit
US20060275230A1 (en) 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
US8137907B2 (en) * 2005-01-03 2012-03-20 Cold Spring Harbor Laboratory Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
EP1858543B1 (en) 2005-01-10 2013-11-27 BioGeneriX AG Glycopegylated granulocyte colony stimulating factor
CA2601777A1 (en) 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US8841259B2 (en) * 2005-02-24 2014-09-23 Joslin Diabetes Center Compositions and methods for treating vascular permeability
US7517906B2 (en) 2005-02-25 2009-04-14 Tetralogic Pharmaceuticals Corporation Dimeric IAP inhibitors
EP1701165A1 (en) 2005-03-07 2006-09-13 Johannes Dr. Coy Therapeutic and diagnostic uses of TKTL1 and inhibitors and activators thereof
US7851189B2 (en) * 2005-03-07 2010-12-14 Boston Scientific Scimed, Inc. Microencapsulated compositions for endoluminal tissue engineering
WO2006105448A2 (en) 2005-03-30 2006-10-05 Minerva Biotechnologies Corporation Proliferation of muc1 expressing cells
ES2720288T3 (es) 2005-03-30 2019-07-19 Minerva Biotechnologies Corp Proliferación de células que expresan MUC1
UA97943C2 (ru) 2005-03-31 2012-04-10 ГлаксоСмитКлайн Байолоджикалз с.а. Вакцина против инфекции chlamydia
US20060228384A1 (en) * 2005-04-06 2006-10-12 Sequoia Sciences, Inc. Control of biofilm with a biofilm inhibitor
EP2386571B1 (en) 2005-04-08 2016-06-01 ratiopharm GmbH Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
KR20070122563A (ko) 2005-04-19 2007-12-31 일라이 릴리 앤드 캄파니 질병에의 면역학적 개입을 위한 1가 및 다가 합성 다당류항원
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
PT2457926E (pt) 2005-04-29 2014-11-25 Glaxosmithkline Biolog Sa Método para prevenção ou tratamento de uma infecção por m. tuberculosis
CA2591586A1 (en) 2005-05-05 2006-11-09 Antisense Pharma Gmbh Dosage of oligonucleotides
US20080193543A1 (en) * 2005-05-17 2008-08-14 Brown University Research Foundation Drug Delivery Formulations For Targeted Delivery
US8354384B2 (en) * 2005-06-23 2013-01-15 Yale University Anti-aging micrornas
ATE530569T1 (de) 2005-07-01 2011-11-15 Forsyth Dental In Ry For Children Fa Assays zum nachweis von tuberkulose- antigenen, und impfstoffe
US20070014739A1 (en) * 2005-07-14 2007-01-18 Eldridge Gary R Compositions and methods for controlling biofilms and bacterial infections
JP4997239B2 (ja) 2005-07-22 2012-08-08 ワイズ・エー・シー株式会社 抗ｃｄ２６抗体およびその使用方法
NZ594275A (en) 2005-07-25 2013-04-26 Emergent Product Dev Seattle B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
CN101600475A (zh) 2005-07-27 2009-12-09 佛罗里达大学研究基金会有限公司 修正蛋白质错误折叠的小型化合物及其使用
JP2009509128A (ja) * 2005-08-09 2009-03-05 テトラロジック ファーマシューティカルズ コーポレーション 増殖性疾患の治療
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
TW201402124A (zh) 2005-08-19 2014-01-16 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
US8507439B2 (en) 2005-08-29 2013-08-13 Angela Shashoua Neuroprotective and neurorestorative method and compositions
US20080021198A1 (en) * 2005-10-12 2008-01-24 Yigong Shi Modulators of protein phosphatase 2A and PP2A methyl esterase
US8658608B2 (en) * 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
CN102517292B (zh) 2005-11-25 2014-12-24 佐蒂斯比利时股份有限公司 免疫刺激性寡核糖核苷酸
US20080280834A1 (en) * 2005-12-01 2008-11-13 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compounds and methods for inhibiting apoptosis
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
US8859209B2 (en) * 2006-01-12 2014-10-14 Carviar Aps Reimmunization and antibody design
EP1981905B1 (en) 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Chlamydia vaccine
WO2007109583A2 (en) 2006-03-17 2007-09-27 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject
ES2776100T3 (es) 2006-03-31 2020-07-29 Massachusetts Inst Technology Sistema para el suministro dirigido de agentes terapéuticos
CA2648718A1 (en) 2006-04-07 2007-10-18 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US8859233B2 (en) * 2006-05-02 2014-10-14 Carviar Aps Method for immunizing an avian species
US10522240B2 (en) 2006-05-03 2019-12-31 Population Bio, Inc. Evaluating genetic disorders
US7702468B2 (en) 2006-05-03 2010-04-20 Population Diagnostics, Inc. Evaluating genetic disorders
MX380352B (es) 2006-06-12 2025-03-12 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
RU2453335C2 (ru) 2006-06-20 2012-06-20 Трансжене С.А. Рекомбинантная вирусная вакцина
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
MX2009000824A (es) 2006-07-24 2009-02-04 Tetralogic Pharmaceuticals Cor Antagonistas dimericos de las proteinas inhibidoras de la apoptosis.
WO2008014238A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
AR064235A1 (es) * 2006-07-24 2009-03-25 Tetralogic Pharmaceuticals Cor Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer
WO2008014240A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014236A1 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
EP2647712A3 (en) 2006-08-04 2013-11-20 Baxter International Inc Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
US20080153773A1 (en) * 2006-08-08 2008-06-26 Yigong Shi Modulators of phosphotyrosyl phosphatase activator
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
LT2486938T (lt) 2006-09-26 2018-06-25 Infectious Disease Research Institute Vakcinos kompozicija, turinti sintetinio adjuvanto
WO2008147426A2 (en) * 2006-10-04 2008-12-04 The Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
WO2008060780A2 (en) 2006-10-04 2008-05-22 Novo Nordisk A/S Glycerol linked pegylated sugars and glycopeptides
WO2008060791A2 (en) * 2006-10-13 2008-05-22 The Trustees Of The University Of Princeton Modulators of protein phosphatase 2a
RU2373957C2 (ru) 2006-10-13 2009-11-27 Александр Метталинович Тишин Носитель для лекарственных средств и биологически активных веществ для лечения и диагностики и применение его для создания лекарственных средств и способа регулируемой управляемой доставки лекарственного средства или биологически активного вещества с регулируемой десорбцией его
US7645616B2 (en) * 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
WO2008098165A2 (en) 2007-02-09 2008-08-14 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2008109773A2 (en) * 2007-03-06 2008-09-12 Cornell Research Foundation, Inc. Chronic obstructive pulmonary disease susceptibility and related compositions and methods
WO2008116216A1 (en) * 2007-03-22 2008-09-25 Medical College Of Georgia Research Institute, Inc. Compositions and methods for inhibiting cancer metastasis
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
WO2008122039A2 (en) * 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
US20090074828A1 (en) 2007-04-04 2009-03-19 Massachusetts Institute Of Technology Poly(amino acid) targeting moieties
HUE039385T2 (hu) 2007-04-12 2018-12-28 Brigham & Womens Hospital Inc ABCB5 rákterápiás célzása
MX2009011218A (es) 2007-04-17 2010-02-11 Baxter Int Microparticulas de acido nucleico para administracion pulmonar.
US20100179158A1 (en) * 2007-04-20 2010-07-15 Hoffman Charles S Inhibitors of cyclic amp phosphodiesterases
US8747872B2 (en) * 2007-05-02 2014-06-10 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
CN101678098A (zh) * 2007-05-17 2010-03-24 科勒制药集团公司 具有免疫刺激效力的a类寡核苷酸
JP2010532749A (ja) * 2007-06-07 2010-10-14 サーモディクス ファーマシューティカルズ， インコーポレイテッド 質量を削減した長時間作用剤形
AU2008262252B2 (en) 2007-06-08 2013-09-12 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for determining hepatocellular carcinoma subtype and detecting hepatic cancer stem cells
EP2591787A1 (en) 2007-08-13 2013-05-15 Pfizer Inc Combination motif immune stimulatory oligonucleotides with improved activity
US8932558B2 (en) * 2007-10-05 2015-01-13 Plaxgen Inc Multi-subunit biological complexes for treatment of plaque-associated diseases
EP2630967A1 (en) 2007-10-12 2013-08-28 Massachusetts Institute of Technology Vaccine nanotechnology
US8619257B2 (en) 2007-12-13 2013-12-31 Kimberley-Clark Worldwide, Inc. Recombinant bacteriophage for detection of nosocomial infection
US20090274682A1 (en) * 2008-02-05 2009-11-05 The Trustees Of Princeton University Demethylation and inactivation of protein phosphatase 2a
US20090233858A1 (en) * 2008-02-26 2009-09-17 The Trustees Of Princeton University Structure of a protein phosphatase 2a holoenzyme: insights into tau dephosphorylation
AU2009222056A1 (en) * 2008-03-01 2009-09-11 Abraxis Bioscience, Llc Treatment, diagnostic, and method for discovering antagonist using SPARC specific miRNAs
EP3023502A1 (en) 2008-04-10 2016-05-25 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
WO2009126310A2 (en) 2008-04-10 2009-10-15 Massachusetts Institute Of Technology Methods for identification and use of agents targeting cancer stem cells
JP6013733B2 (ja) 2008-04-11 2016-10-25 エマージェント プロダクト デベロップメント シアトル， エルエルシー Ｃｄ３７免疫治療薬および二機能性化学療法薬とのその組合せ
CA2720675C (en) 2008-04-18 2019-08-27 Baxter International Inc. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
US20100227853A1 (en) * 2008-04-18 2010-09-09 Trustees Of Boston College Inhibitors of cyclic amp phosphodiesterases
CA2722589A1 (en) 2008-04-25 2009-10-29 Innate Pharma Improved tlr3 agonist compositions
CN102076853A (zh) * 2008-05-07 2011-05-25 阿布拉西斯生物科学有限责任公司 通过miRNA增强药物疗法
EP2123748A1 (en) 2008-05-20 2009-11-25 Institut Pasteur 2'-5'-oligoadenylate synthetase 3 for preventing and treating positive-sense single-stranded rna virus infection
WO2009151561A2 (en) 2008-06-12 2009-12-17 President And Fellows Of Harvard College Methods and compounds for antimicrobial intervention
EP2318832B1 (en) 2008-07-15 2013-10-09 Academia Sinica Glycan arrays on ptfe-like aluminum coated glass slides and related methods
CA2737146A1 (en) 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Clip inhibitors and methods of modulating immune function
US9273136B2 (en) * 2008-08-04 2016-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human anti-human NKG2D monoclonal antibodies
US8367427B2 (en) 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US8323685B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8399683B2 (en) 2008-09-17 2013-03-19 Tetralogic Pharmaceuticals IAP inhibitors
WO2010033958A1 (en) * 2008-09-22 2010-03-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nuclear factor kappa b pathway inhibitor composition and use of same
CA2740087C (en) 2008-10-08 2019-07-23 Kyphia Pharmaceuticals, Inc. Gaba conjugates and methods of use thereof
KR20200133324A (ko) 2008-10-09 2020-11-27 미네르바 바이오테크놀로지 코포레이션 세포내에서 다능성을 유도하기 위한 방법
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
PT3130923T (pt) 2008-11-14 2020-06-17 Brigham & Womens Hospital Inc Métodos terapêuticos relacionados com células estaminais
EP2376089B1 (en) 2008-11-17 2018-03-14 The Regents of the University of Michigan Cancer vaccine compositions and methods of using the same
WO2010075417A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
WO2010075303A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
US8309356B2 (en) * 2009-04-01 2012-11-13 Yale University Pseudocomplementary oligonucleotides for targeted gene therapy
DK2418945T3 (en) 2009-04-15 2019-02-25 Bmg Pharma S P A Mineral salt-sulfonic acid compositions and methods of use
US9316646B2 (en) 2009-04-23 2016-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ROR1 antibodies
CA2760547C (en) 2009-04-30 2020-03-24 Karlyne Reilly Schweinfurthins and uses thereof
WO2010130374A1 (en) 2009-05-14 2010-11-18 Bayer Animal Health Gmbh Enhanced immune response in avian species
WO2010132532A1 (en) 2009-05-15 2010-11-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services B cell surface reactive antibodies
CA2764374C (en) 2009-06-05 2019-11-19 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
WO2010144611A2 (en) * 2009-06-10 2010-12-16 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
IN2012DN00352A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
CN102596243B (zh) 2009-06-16 2015-10-21 密执安大学评议会 纳米乳剂疫苗
US8283372B2 (en) * 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
WO2011011092A1 (en) 2009-07-22 2011-01-27 University Of Massachusetts Methods and compositions to reduce oxidative stress
JP2013500313A (ja) 2009-07-30 2013-01-07 アンチセンス・ファーマ・ゲーエムベーハー 化学療法薬およびＴＧＦ−β系の阻害剤の組合せ
EP2292260A1 (en) 2009-08-13 2011-03-09 Institut Pasteur Use of mycobacterium bovis BCG killed by extended freeze drying (EFD) for preventing or treating atherosclerosis
EP2287304A1 (en) 2009-08-17 2011-02-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel treatment of patients after stent implantation or balloon dilatation and novel drug eluting stents
HUE032626T2 (en) 2009-08-18 2017-10-30 Ventirx Pharmaceuticals Inc Toll receptor modulator substituted benzoazepines
HUE031797T2 (en) 2009-08-18 2017-08-28 Ventirx Pharmaceuticals Inc Substituted benzoazepines as Toll-like receptor modulators
JP2013505022A (ja) 2009-09-16 2013-02-14 バクサート インコーポレーティッド Ｈ１ｎ１感染を予防するための免疫戦略の方法
JP5934099B2 (ja) 2009-10-01 2016-06-15 アメリカ合衆国 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用
US20110104138A1 (en) 2009-11-03 2011-05-05 Institut Pasteur Use of the innate immunity gene oasl for preventing or treating infection with negative strand rna viruses
DK2501716T3 (en) 2009-11-19 2015-04-07 Solis Biodyne Oü Formations to increase polypeptidstabilitet and activity and related practices
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
KR20130088002A (ko) 2010-01-13 2013-08-07 재단법인 한국파스퇴르연구소 항-감염성 피리도(1,2-ａ)피리미딘
CA2786969C (en) 2010-01-27 2018-07-24 Glaxosmithkline Biologicals S.A. Modified tuberculosis antigens
US9556248B2 (en) 2010-03-19 2017-01-31 The Board Of Trustees Of The Leland Stanford Junior University Hepatocyte growth factor fragments that function as potent met receptor agonists and antagonists
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
US20110262406A1 (en) 2010-04-21 2011-10-27 Yale University Compositions and methods for targeted inactivation of hiv cell surface receptors
US20110293585A1 (en) 2010-04-21 2011-12-01 Helix Therapeutics, Inc. Compositions and methods for treatment of lysosomal storage disorders
KR20130107203A (ko) 2010-05-04 2013-10-01 더 브리검 앤드 우먼즈 하스피털, 인크. 섬유증의 검출 및 치료
WO2011138032A2 (en) 2010-05-05 2011-11-10 Artemev, Timur Universal influenza vaccines and methods for their generation
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
EP2595613B1 (en) 2010-07-22 2019-01-09 The U.S.A. as represented by the Secretary, Department of Health and Human Services Compounds for use in a method of preventing or treating viral infection
CN103392182B (zh) 2010-08-02 2017-07-04 众有生物有限公司 用于发现遗传疾病中致病突变的系统和方法
AR083533A1 (es) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
AU2011332815A1 (en) 2010-11-23 2013-05-30 Presage Biosciences, Inc. Therapeutic methods and compositions for solid delivery
AU2011336650B2 (en) 2010-12-01 2016-12-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ROR1 antibodies
AU2011347464B2 (en) 2010-12-22 2016-08-25 Elanco Animal Health Gmbh Enhanced immune response in bovine species
AU2012205486B2 (en) 2011-01-12 2017-02-02 Array Biopharma, Inc. Substituted benzoazepines as toll-like receptor modulators
PL2663555T3 (pl) 2011-01-12 2017-08-31 Ventirx Pharmaceuticals, Inc. Podstawione benzoazepiny jako modulatory receptora toll-podobnego
CN103459598B (zh) 2011-02-03 2016-08-10 米尔纳医疗股份有限公司 Mir-124的合成模拟物
MY165507A (en) 2011-02-03 2018-03-28 Mirna Therapeutics Inc Synthetic mimics of mir-34
ES2624131T3 (es) 2011-03-08 2017-07-13 3-V Biosciences, Inc. Moduladores heterocíclicos de la síntesis de lípidos
DK2683736T3 (en) 2011-03-09 2018-04-23 Cell Signaling Technology Inc METHODS AND REAGENTS FOR CREATING MONOCLONAL ANTIBODIES
EP4086338A1 (en) 2011-03-17 2022-11-09 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
EA027236B1 (ru) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
PT2694549T (pt) 2011-04-08 2018-11-22 Us Health Recetores de antigénio quimérico variante iii de recetor de fator de crescimento antiepidérmico e utilização do mesmo para o tratamento de cancro
EP2699266B1 (en) 2011-04-21 2019-06-12 Trustees Of Tufts College Compositions and methods for stabilization of active agents
ES2583877T3 (es) 2011-06-01 2016-09-22 Janus Biotherapeutics, Inc. Moduladores novedosos del sistema inmunitario
JP6093759B2 (ja) 2011-06-01 2017-03-08 ジャナス バイオセラピューティクス，インク． 新規の免疫系調節剤
BR112013032199A2 (pt) 2011-06-14 2017-12-12 Bikam Pharmaceuticals Inc ligantes de ligação à opsina, composições e métodos de utilização
EP2720706B1 (en) 2011-06-17 2020-08-05 University of Tennessee Research Foundation Group a streptococcus multivalent vaccine
AU2012273153A1 (en) 2011-06-21 2013-05-02 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
CA2842321C (en) 2011-07-18 2022-05-03 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
US10765654B2 (en) 2011-07-19 2020-09-08 University Of Vermont And State Agricultural College Methods and compounds for treating cancer
US8324264B1 (en) 2011-07-22 2012-12-04 Sequoia Sciences, Inc. Inhibitors of bacterial biofilms and related methods
WO2013020044A1 (en) 2011-08-03 2013-02-07 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center Treatment of fibrosis using microrna-19b
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
AU2012318694B2 (en) 2011-10-04 2016-12-22 Janus Biotherapeutics, Inc. Novel imidazole quinoline-based immune system modulators
WO2013054200A2 (en) 2011-10-10 2013-04-18 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
EP2768945B1 (en) 2011-10-17 2022-01-05 Minerva Biotechnologies Corporation Media for stem cell proliferation and induction
WO2013059593A1 (en) 2011-10-20 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
CN104023760A (zh) 2011-10-28 2014-09-03 普莱萨格生命科学公司 药物递送方法
WO2013067451A2 (en) 2011-11-04 2013-05-10 Population Diagnostics Inc. Methods and compositions for diagnosing, prognosing, and treating neurological conditions
JP6368243B2 (ja) 2011-11-11 2018-08-08 フレッド ハッチンソン キャンサー リサーチ センター がんのためのサイクリンａ１に標的化されたｔ細胞免疫療法
WO2013082000A1 (en) 2011-11-30 2013-06-06 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
WO2013082275A1 (en) 2011-11-30 2013-06-06 Trustees Of Boston College Inhibitors of phosphodiesterases 11 (pde11) and methods of use to elevate cortisol production
CN104363892A (zh) 2012-02-07 2015-02-18 传染性疾病研究院 包含tlr4激动剂的改进佐剂制剂及其使用方法
US10407724B2 (en) 2012-02-09 2019-09-10 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
CN103251941A (zh) * 2012-02-16 2013-08-21 海南大学 动物病毒性疫苗脉冲释放系统、其制备方法及用途
BR112014021388A2 (pt) 2012-02-29 2017-07-18 Ethicon Endo Surgery Inc composições de microbiota e métodos rela-cionados às mesmas
US20130236484A1 (en) 2012-03-08 2013-09-12 Detectogen Inc. Leishmaniasis antigen detection assays and vaccines
EP2828290B1 (en) 2012-03-23 2018-08-15 The United States of America, represented by the Secretary, Department of Health and Human Services Anti-mesothelin chimeric antigen receptors
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
US9790278B2 (en) 2012-05-07 2017-10-17 The Trustees Of Dartmouth College Anti-B7-H6 antibody, fusion proteins, and methods of using the same
AU2013262691B2 (en) 2012-05-16 2018-12-20 Immune Design Corp. Vaccines for HSV-2
CN104582715A (zh) 2012-07-11 2015-04-29 佛蒙特大学及州农业学院 用于代谢调节的方法和组合物
EP2873674B1 (en) 2012-07-13 2020-05-06 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
CA2880701A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
EP2887942A4 (en) 2012-08-21 2016-08-31 Genesys Res Inst COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING ANTHRACYCLIN-INDUCED CARDIOTOXICITY
EP2895621B1 (en) 2012-09-14 2020-10-21 Population Bio, Inc. Methods and compositions for diagnosing, prognosing, and treating neurological conditions
CA2922005A1 (en) 2012-09-27 2014-04-03 Population Diagnostics, Inc. Methods and compositions for screening and treating developmental disorders
US9228184B2 (en) 2012-09-29 2016-01-05 Dynavax Technologies Corporation Human toll-like receptor inhibitors and methods of use thereof
WO2014055624A1 (en) 2012-10-02 2014-04-10 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods relating to dna-sensing pathway related conditions
ES2718903T3 (es) 2012-10-24 2019-07-05 Us Health Receptores de antígenos quiméricos M971
US10106778B2 (en) 2012-11-08 2018-10-23 Whitehead Institute For Biomedical Research Selective targeting of cancer stem cells
US9872851B2 (en) 2012-12-12 2018-01-23 The Charlotte-Mecklenburg Hospital Authority Methods of treating portal hypertension
US9750718B2 (en) 2012-12-12 2017-09-05 The Charlotte-Mecklenburg Hospital Authority Methods of treating hepatic fibrosis and associated diseases by regulating Rev-ERB activity
ES2689878T3 (es) 2013-02-21 2018-11-16 Boehringer Ingelheim Vetmedica Gmbh Proteínas H5 del virus de la gripe H5N1 para su uso como un medicamento
CN118028464A (zh) 2013-03-14 2024-05-14 儿童医学中心公司 Cd36鉴定癌症对象以用于治疗的用途
WO2014159060A1 (en) 2013-03-14 2014-10-02 Hallux, Inc. Method of treating infections, diseases or disorders of nail unit
US20160046679A1 (en) 2013-03-15 2016-02-18 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
US11376329B2 (en) 2013-03-15 2022-07-05 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
US20160052985A1 (en) 2013-04-04 2016-02-25 Ieo - Istituto Europeo Di Oncologia Srl Thymic stromal lymphopoietin fragments and uses thereof
KR102039520B1 (ko) 2013-04-18 2019-11-01 이뮨 디자인 코포레이션 암 치료에 이용하기 위한 gla 단일요법
WO2014182635A1 (en) 2013-05-08 2014-11-13 Baldwin Megan E Biomarkers for age-related macular degeneration (amd)
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
CN112957365A (zh) 2013-06-25 2021-06-15 沃尔特和伊利莎豪医学研究所 治疗细胞内感染的方法
WO2014210397A1 (en) 2013-06-26 2014-12-31 Academia Sinica Rm2 antigens and use thereof
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
US10231993B2 (en) 2013-06-27 2019-03-19 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
WO2015006543A1 (en) 2013-07-10 2015-01-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for predicting and detecting tumor metastasis in kidney cancer
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
US10633714B2 (en) 2013-07-21 2020-04-28 Pendulum Therapeutics, Inc. Methods and systems for microbiome characterization, monitoring and treatment
EP3041484B1 (en) 2013-09-06 2021-03-03 Academia Sinica Human inkt cell activation using glycolipids with altered glycosyl groups
SG11201603134XA (en) 2013-10-21 2016-05-30 Salk Inst For Biological Studi Mutated fibroblast growth factor (fgf) 1 and methods of use
CA2928700C (en) 2013-11-01 2019-01-15 University Of Oslo Albumin variants and uses thereof
DK3069138T3 (en) 2013-11-15 2019-04-08 Univ Oslo Hf CTL PEPTID EPITOPES AND ANTIGEN-SPECIFIC T-CELLS, METHODS OF RECOGNITION THEREOF, AND APPLICATIONS THEREOF
WO2015084513A1 (en) 2013-12-06 2015-06-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
WO2015095604A2 (en) 2013-12-18 2015-06-25 President And Fellows Of Harvard College Methods and assays relating to circulating tumor cells
EP3083583B1 (en) 2013-12-20 2020-11-18 Sagimet Biosciences Inc. Heterocyclic modulators of lipid synthesis and combinations thereof
KR102335142B1 (ko) 2014-01-07 2021-12-06 새지메트 바이오사이언시스, 인코포레이티드 암 및 바이러스 감염에 대해서 사용하기 위한 지질 합성의 헤테로사이클릭 조절인자
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
WO2015108046A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
JP2017507118A (ja) 2014-01-16 2017-03-16 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ がんの処置および検出のための組成物および方法
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
BR112016016672A2 (pt) 2014-01-21 2017-08-08 Immune Design Corp Uso de uma composição
CA2939581C (en) 2014-02-20 2024-01-23 Vaxart, Inc. Formulations for small intestinal delivery
BR112016019837A2 (pt) 2014-02-28 2017-10-17 Bayer Animal Health Gmbh plasmídeos imunoestimuladores
AU2015229227B2 (en) 2014-03-14 2021-03-18 University Of Washington Genomic insulator elements and uses thereof
CA2943802A1 (en) 2014-03-26 2015-10-01 Children's Medical Center Corporation Cyclic prosaposin peptides and uses thereof
EP3129767B1 (en) 2014-03-27 2021-09-01 Academia Sinica Reactive labelling compounds and uses thereof
EP3122375B1 (en) 2014-03-28 2021-03-03 University of Washington through its Center for Commercialization Breast and ovarian cancer vaccines
US10398672B2 (en) 2014-04-29 2019-09-03 Whitehead Institute For Biomedical Research Methods and compositions for targeting cancer stem cells
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
EP4331618A3 (en) 2014-05-09 2024-06-12 Yale University Hyperbranched polyglycerol-coated particles and methods of making and using thereof
AU2015267051B2 (en) 2014-05-27 2022-03-17 Academia Sinica Fucosidase from bacteroides and methods using the same
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
IL249188B2 (en) 2014-05-27 2024-03-01 Academia Sinica Anti-her2 glycoantibodies and uses thereof
AU2015267047A1 (en) 2014-05-27 2017-01-05 Academia Sinica Anti-CD20 glycoantibodies and uses thereof
CA2950433A1 (en) 2014-05-28 2015-12-03 Academia Sinica Anti-tnf-alpha glycoantibodies and uses thereof
CN106715458A (zh) 2014-07-18 2017-05-24 华盛顿大学 癌症疫苗组合物及其使用方法
EP3183251A4 (en) 2014-08-22 2017-12-27 Janus Biotherapeutics, Inc. Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
GB2558326B (en) 2014-09-05 2021-01-20 Population Bio Inc Methods and compositions for inhibiting and treating neurological conditions
TWI745275B (zh) 2014-09-08 2021-11-11 中央研究院 使用醣脂激活人類ｉＮＫＴ細胞
CA2961609C (en) 2014-09-17 2023-03-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 antibodies (b7h3)
WO2016054240A1 (en) 2014-09-30 2016-04-07 Sean Dalziel Fixed dose combinations for the treatment of viral diseases
US11083788B2 (en) 2014-10-10 2021-08-10 The Regents Of The University Of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
WO2016061199A2 (en) 2014-10-14 2016-04-21 Research Development Foundation Methods for generating engineered enzymes
GB2551642B (en) 2014-10-31 2020-09-23 Pendulum Therapeutics Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
CA2972072A1 (en) 2015-01-24 2016-07-28 Academia Sinica Novel glycan conjugates and methods of use thereof
US11746159B2 (en) 2015-02-10 2023-09-05 Minerva Biotechnologies Corporation Humanized anti-MUC1* antibodies
EP3258953B1 (en) 2015-02-18 2023-07-05 University of Vermont and State Agricultural College Mcj polypeptides for use in treating cancer
EP4226936A3 (en) 2015-03-05 2023-09-27 Northwestern University Non-neuroinvasive viruses and uses thereof
ES2910049T3 (es) 2015-03-19 2022-05-11 Sagimet Biosciences Inc Moduladores heterocíclicos de la síntesis de lípidos
WO2016154585A1 (en) 2015-03-26 2016-09-29 Charles Sentman Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
ES2794628T3 (es) 2015-04-15 2020-11-18 Univ Massachusetts Composiciones y métodos para la reactivación de cromosomas XI
CN108136021A (zh) 2015-04-25 2018-06-08 综合医院公司 用于治疗癌症的抗驱走性试剂和抗癌剂联合疗法和组合物
KR20180033499A (ko) 2015-06-05 2018-04-03 아이바이오, 인크. 섬유증을 치료하는데 사용하기 위한 엔도스타틴 단편 및 변이체
EA201792512A1 (ru) 2015-06-12 2018-06-29 Вэксарт, Инк. Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник
EP3831844B1 (en) 2015-06-26 2024-03-13 Prindex S.r.l. Diagnosis and therapy of multiple sclerosis
EP3319636A2 (en) 2015-07-10 2018-05-16 University of Vermont and State Agricultural College Mcj inhibitors for use in treating drug-induced diseases and conditions
MX2018001251A (es) 2015-07-31 2018-03-26 Bayer Animal Health Gmbh Respuesta inmunitaria potenciada de las especies porcinas.
WO2017024114A1 (en) 2015-08-06 2017-02-09 President And Fellows Of Harvard College Improved microbe-binding molecules and uses thereof
KR20180039162A (ko) 2015-08-20 2018-04-17 아소시아시온 센트로 데 인베스티가시온 코오페라티바 엔 비오시엔시아스-시스 비오구네 간 질환 및 병태를 치료하기 위한 방법 및 조성물
WO2017049192A1 (en) 2015-09-17 2017-03-23 University Of Massachusetts Compositions and methods for modulating fmr1 expression
AU2016324160A1 (en) 2015-09-18 2018-04-26 The General Hospital Corporation Dba Massachusetts General Hospital Localized delivery of anti-fugetactic agent for treatment of cancer
MY197562A (en) 2015-09-21 2023-06-23 Aptevo Res & Development Llc Cd3 binding polypeptides
EP3383418B1 (en) 2015-12-04 2021-10-20 Board of Regents, The University of Texas System Slc45a2 peptides for immunotherapy
WO2017127664A1 (en) 2016-01-20 2017-07-27 The Scripps Research Institute Ror1 antibody compositions and related methods
WO2017127702A1 (en) 2016-01-20 2017-07-27 The Scripps Research Institute Ror2 antibody compositions and related methods
JP2019508037A (ja) 2016-02-16 2019-03-28 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔ 標的化遺伝子編集を増強するための組成物およびその使用方法
WO2017143061A1 (en) 2016-02-16 2017-08-24 Yale University Compositions and methods for treatment of cystic fibrosis
CA3016170A1 (en) 2016-03-08 2017-09-14 Academia Sinica Methods for modular synthesis of n-glycans and arrays thereof
WO2017173334A1 (en) 2016-04-01 2017-10-05 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
US11168145B2 (en) 2016-04-08 2021-11-09 Zielbio, Inc. Plectin-1 binding antibodies and uses thereof
JP2019527065A (ja) 2016-05-04 2019-09-26 アビリタ バイオ，インク． 複数膜貫通型タンパク質を調製する方法とプラットフォーム
EP3454891A4 (en) 2016-05-10 2019-12-25 The Regents of The University of Michigan EMULSION ADJUVANS FOR INTRAMUSCULAR, INTRADERMAL AND SUBCUTANEOUS ADMINISTRATION
KR102483033B1 (ko) 2016-05-16 2022-12-30 액세스 투 어드밴스드 헬스 인스티튜트 페길화된 리포솜 및 이의 용도
DK3458475T3 (da) 2016-05-16 2022-09-12 Access To Advanced Health Inst Formulering, der indeholder tlr-agonist, og anvendelsesfremgangsmåder
EP3464366A1 (en) 2016-05-27 2019-04-10 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Flt3-specific chimeric antigen receptors and methods using same
WO2017207623A1 (en) 2016-05-31 2017-12-07 Université de Lausanne Mirna as biomarkers and regulators of cancer stem cells
IL298227B2 (en) 2016-06-01 2024-09-01 Access To Advanced Health Inst Nanoalum particles containing a sizing agent
US20190322643A1 (en) 2016-06-29 2019-10-24 Georgia State University Research Foundation, Inc. Histone deacetylase and histone methyltransferase inhibitors and methods of making and use of the same
US20190201414A1 (en) 2016-07-01 2019-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Inhibitor of heme degradation for use to improve antibiotic treatment of mycobacterium tuberculosis infection
BR112019001599A2 (pt) 2016-07-26 2019-10-01 Bayer Animal Health Gmbh fertilidade aumentada em espécies bovinas
KR102588027B1 (ko) 2016-08-22 2023-10-12 초 파마 인크. 항체, 결합 단편 및 사용 방법
WO2018049124A1 (en) 2016-09-09 2018-03-15 The General Hospital Corporation Hsp fusion protein with anti-chemorepellant agent for treatment of infectious disease
US11364264B2 (en) 2016-09-09 2022-06-21 The General Hospital Corporation Ex vivo antigen-presenting cells or activated CD-positive T cells for treatment of cancer
US11325951B2 (en) 2016-09-09 2022-05-10 The General Hospital Corporation HSP fusion protein with anti-chemorepellant agent for treatment of cancer
CN110035763B (zh) 2016-09-27 2022-11-15 瑞阳公司 用于治疗寄生虫病的组合物
US11725232B2 (en) 2016-10-31 2023-08-15 The Hong Kong University Of Science And Technology Compositions, methods and kits for detection of genetic variants for alzheimer's disease
CA3042700A1 (en) 2016-11-07 2018-05-11 University Of Massachusetts Therapeutic targets for facioscapulohumeral muscular dystrophy
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
US10240205B2 (en) 2017-02-03 2019-03-26 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
US10786471B2 (en) 2017-02-06 2020-09-29 Massachusetts Institute Of Technology Methods and products related to glutaminase inhibitors
CA3056797A1 (en) 2017-03-16 2018-09-20 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
US11547694B2 (en) 2017-03-23 2023-01-10 The General Hospital Corporation CXCR4/CXCR7 blockade and treatment of human papilloma virus-associated disease
US11920125B2 (en) 2017-03-27 2024-03-05 Tenfold Technologies, LLC Methods and agricultural compositions for preventing or controlling plant diseases
US12274732B2 (en) 2017-03-27 2025-04-15 Tenfold Technologies, LLC Anti-pathogen composition and methods of use thereof
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery
US11225512B2 (en) 2017-04-27 2022-01-18 University Of New Hampshire Compositions and methods for ceramide-elevating therapeutic strategies
US11390683B2 (en) 2017-05-18 2022-07-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin polypeptides and proteins
SG11201911930SA (en) 2017-06-11 2020-01-30 Molecular Express Inc Methods and compositions for substance use disorder vaccine formulations and uses thereof
WO2018232257A1 (en) 2017-06-15 2018-12-20 Infectious Disease Research Institute Nanostructured lipid carriers and stable emulsions and uses thereof
EP3649242A2 (en) 2017-07-06 2020-05-13 National University of Singapore Methods of inhibiting cell proliferation and mettl8 activity
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
JP2020526537A (ja) 2017-07-14 2020-08-31 ユニバーシティ オブ マサチューセッツ 炎症を処置するための方法および組成物
US11447546B2 (en) 2017-07-20 2022-09-20 Nbe-Therapeutics Ag Human antibodies binding to ROR2
SG11202000846WA (en) 2017-08-07 2020-02-27 Nbe Therapeutics Ag Anthracycline-based antibody drug conjugates having high in vivo tolerability
EP3675882A4 (en) 2017-08-30 2021-07-28 Pendulum Therapeutics, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
WO2019048928A1 (en) 2017-09-07 2019-03-14 University Of Oslo VACCINE MOLECULES
WO2019048936A1 (en) 2017-09-07 2019-03-14 University Of Oslo VACCINE MOLECULES
WO2019108656A1 (en) 2017-11-28 2019-06-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Microbicidal composition
WO2019154884A1 (en) 2018-02-07 2019-08-15 Ecole Polytechnique Federale De Lausanne (Epfl) Method for determining cancer invasiveness and patient prognosis
CN112119092A (zh) 2018-02-12 2020-12-22 无糖尿病公司 改进的拮抗性抗人cd40单克隆抗体
EP3752194A4 (en) 2018-02-13 2022-03-16 Checkmate Pharmaceuticals, Inc. ANTI-TUMOR IMMUNOTHERAPY COMPOSITIONS AND METHODS
KR20210006905A (ko) 2018-04-09 2021-01-19 체크메이트 파마슈티칼스 바이러스-유사 입자 내로의 올리고뉴클레오타이드의 포장
WO2019204154A1 (en) 2018-04-18 2019-10-24 Reyoung Corporation Compositions and methods for treating liver cancer
US11826315B2 (en) 2018-04-19 2023-11-28 Tvardi Therapeutics STAT3 inhibitors
WO2019217164A1 (en) 2018-05-09 2019-11-14 Reyoung Corporation Compositions and methods for treating cancer and other diseases
CA3100276A1 (en) 2018-06-06 2019-12-12 Massachusetts Institute Of Technology Circular rna for translation in eukaryotic cells
CA3103740A1 (en) 2018-06-29 2020-01-02 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
WO2020001657A1 (en) 2018-06-29 2020-01-02 Wuhan Neurophth Biological Technology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
AU2019306649A1 (en) 2018-07-19 2021-02-04 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
WO2020033700A1 (en) 2018-08-08 2020-02-13 Pml Screening, Llc Mathods for assessing the risk of developing progressive multifocal leukoencephalopathy caused by john cunningham virus by genetic testing
AU2019323434A1 (en) 2018-08-20 2021-02-25 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
ES2990218T3 (es) 2018-08-22 2024-11-29 Bacainn Biotherapeutics Ltd Composiciones de ciclosporina y métodos de uso
BR112021003823A2 (pt) 2018-08-31 2021-05-25 Yale University composição, composição farmacêutica e método para modificar o genoma de uma célula
SG11202101975RA (en) 2018-08-31 2021-03-30 Univ Yale Compositions and methods for enhancing donor oligonucleotide-based gene editing
JP7320601B2 (ja) 2018-09-11 2023-08-03 上▲海▼市公共▲衛▼生▲臨▼床中心 広域スペクトルな抗インフルエンザワクチン免疫原及びその使用
CA3114911A1 (en) 2018-10-04 2020-04-09 Rutgers, The State University Of New Jersey Methods of reducing type 2 cytokine-mediated inflammation using neuromedin peptides
US11266617B2 (en) 2018-10-16 2022-03-08 Massachusetts Institute Of Technology Beta-hydroxybutyrate encapsulated PLGA nanoparticle compositions
CN117925571A (zh) 2018-10-19 2024-04-26 德克萨斯州大学系统董事会 工程化长散在元件（line）转座子及其使用方法
WO2020102454A1 (en) 2018-11-13 2020-05-22 Regents Of The University Of Minnesota Cd40 targeted peptides and uses thereof
EP3883562A4 (en) 2018-11-21 2022-08-03 Tremeau Pharmaceuticals, Inc. PURIFIED FORMS OF ROFECOXIB AND METHODS OF MAKING AND USING
EP3677693A1 (en) 2019-01-03 2020-07-08 Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO Transpochimeric gene trancripts (tcgts) as cancer biomarkers
PH12021551676A1 (en) 2019-01-18 2022-03-07 Janssen Biotech Inc Gprc5d chimeric antigen receptors and cells expressing the same
SG11202108150RA (en) 2019-01-30 2021-08-30 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
WO2020186187A1 (en) 2019-03-13 2020-09-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating bladder and urethra dysfunction and disease
JP2022527569A (ja) 2019-03-21 2022-06-02 ミトセラピューティクス・エルエルシー 治療剤の標的化送達のための多価リガンドクラスター
WO2020210719A1 (en) 2019-04-10 2020-10-15 Elevatebio Management, Inc. Flt3-specific chimeric antigen receptors and methods of using the same
EP3972653A1 (en) 2019-05-22 2022-03-30 Massachusetts Institute of Technology Circular rna compositions and methods
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
US20220243211A1 (en) 2019-06-21 2022-08-04 Yale University Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
WO2020257779A1 (en) 2019-06-21 2020-12-24 Yale University Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
WO2021011529A1 (en) 2019-07-15 2021-01-21 Rovaxa Opioid growth factor receptor (ogfr) antagonists, in particular naloxone and/or naltrexone for treating cancer
MX2022001058A (es) 2019-07-26 2022-02-14 Janssen Biotech Inc Receptor de antigeno quimerico (car) anti-hk2.
JP2022541332A (ja) 2019-07-26 2022-09-22 ヤンセン バイオテツク，インコーポレーテツド カリクレイン関連ペプチダーゼ２抗原結合ドメインを含むタンパク質及びその使用
US20220280656A1 (en) 2019-07-31 2022-09-08 Yale University Compositions and methods for treating sickle cell disease
CN112390894A (zh) 2019-08-12 2021-02-23 广东东阳光药业有限公司 嵌合抗原受体及其应用
KR20220061977A (ko) 2019-08-12 2022-05-13 퓨리노미아 바이오테크, 아이엔씨. Cd39 발현 세포의 adcc 표적화를 통해 t 세포 매개 면역 반응을 촉진 및 강화하기 위한 방법 및 조성물
KR20220041934A (ko) 2019-08-16 2022-04-01 얀센 바이오테크 인코포레이티드 개선된 기능을 갖는 치료용 면역 세포 및 이의 제조 방법
CN115151275A (zh) 2019-08-30 2022-10-04 耶鲁大学 用于向细胞递送核酸的组合物和方法
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
WO2021099944A1 (en) 2019-11-18 2021-05-27 Janssen Biotech, Inc. Anti-cd79 chimeric antigen receptors, car-t cells, and uses thereof
CN113025633B (zh) 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
EP3868396A1 (en) 2020-02-20 2021-08-25 Enthera S.R.L. Inhibitors and uses thereof
EP4107267A1 (en) 2020-02-21 2022-12-28 Mitotherapeutix LLC Compositions and methods for inhibiting expression of methylation-controlled j-protein (mcj)
PE20240019A1 (es) 2020-03-13 2024-01-04 Janssen Biotech Inc Materiales y metodos para la union de siglec-3/cd33
US20230181672A1 (en) 2020-05-07 2023-06-15 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
WO2021226519A1 (en) 2020-05-08 2021-11-11 Georgiamune Llc Akt3 modulators
CN116322788A (zh) 2020-05-19 2023-06-23 奥纳治疗公司 环状rna组合物和方法
CN115803084A (zh) 2020-05-21 2023-03-14 得克萨斯大学体系董事会 具有vgll1特异性的t细胞受体和其用途
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
KR20230060501A (ko) 2020-08-03 2023-05-04 얀센 바이오테크 인코포레이티드 바이러스 치료제에서 다방성 생체이동을 위한 재료 및 방법
US20230265214A1 (en) 2020-08-31 2023-08-24 Yale University Compositions and methods for delivery of nucleic acids to cells
CA3173951A1 (en) 2020-09-04 2022-03-10 Emily VOIGT Genetically-adjuvanted rna vaccines
AU2021336217A1 (en) 2020-09-04 2023-04-20 Access To Advanced Health Institute Live-attenuated rna hybrid vaccine technology
US20230310323A1 (en) 2020-09-04 2023-10-05 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
US20240042053A1 (en) 2020-10-16 2024-02-08 University Of Georgia Research Foundation, Inc. Glycoconjugates
EP4059498A1 (en) 2021-03-16 2022-09-21 Centre Hospitalier Universitaire Vaudois (CHUV) Methods and compositions for treating conditions associated with hypermineralization
MX2023011273A (es) 2021-03-24 2023-12-14 Janssen Biotech Inc Anticuerpo dirigido a cd22 y cd79b.
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
WO2022237974A1 (en) 2021-05-12 2022-11-17 Ecole Polytechnique Federale De Lausanne (Epfl) Krab-containing zinc finger protein and cancer
CN115404240A (zh) 2021-05-28 2022-11-29 上海环码生物医药有限公司 制备环形rna的构建体、方法及其用途
US20240279687A1 (en) 2021-06-07 2024-08-22 Yale University Peptide nucleic acids for spatiotemporal control of crispr-cas binding
WO2022271955A1 (en) 2021-06-23 2022-12-29 Musc Foundation For Research Development Novel targeted shrna nanoparticles for cancer therapy
WO2023280157A1 (zh) 2021-07-05 2023-01-12 武汉纽福斯生物科技有限公司 一种抗vegf抗体体内表达系统的构建和应用
JP2024529033A (ja) 2021-08-06 2024-08-01 ウーハン ニューロフス バイオテクノロジー リミテッド カンパニー Ｎｄ４変異により引き起こされるレーベル遺伝性視神経症を治療するための組成物及び方法
JP2024534053A (ja) 2021-08-25 2024-09-18 アイバイオ， インク． 抗ｃｄ２５抗体
WO2023046322A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceutica Nv Proteins comprising cd20 binding domains, and uses thereof
TW202332694A (zh) 2021-10-07 2023-08-16 英商阿凡克塔生命科學公司 血清半衰期延長之ｐｄ－ｌ１結合多肽
EP4413038A1 (en) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Pd-l1 binding affimers
KR20240107139A (ko) 2021-11-08 2024-07-08 오나 테라퓨틱스, 인코포레이티드 원형 폴리뉴클레오티드를 전달하기 위한 지질 나노입자 조성물
MX2024005862A (es) 2021-11-16 2024-07-10 Shanghai Argo Biopharmaceutical Co Ltd Composiciones y metodos para inhibir la expresion de la proteina angiotensinogeno (agt).
CA3235672A1 (en) 2021-11-29 2023-06-01 Shanghai Argo Biopharmaceutical Co., Ltd. Compositions and methods for inhibiting expression of hepatitis b virus (hbv) protein
TW202345865A (zh) 2022-01-24 2023-12-01 大陸商上海舶望製藥有限公司 抑制LPA(Apo(a))蛋白表達的組合物和方法
WO2023153876A1 (ko) 2022-02-10 2023-08-17 주식회사 아피셀테라퓨틱스 Cd40l에 특이적으로 결합하는 스테핀 a 단백질 변이체 및 이의 용도
KR20250006965A (ko) 2022-04-29 2025-01-13 퓨리노미아 바이오테크, 아이엔씨. 호산구에 의해 유발되는 질환 및 장애의 치료를 위한 방법 및 조성물
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
WO2023231959A2 (en) 2022-05-30 2023-12-07 Shanghai Circode Biomed Co., Ltd Synthetic circular rna compositions and methods of use thereof
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
WO2024055034A1 (en) 2022-09-09 2024-03-14 Yale University Proteolysis targeting antibodies and methods of use thereof
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin
EP4602078A2 (en) 2022-10-11 2025-08-20 Yale University Compositions and methods of using cell-penetrating antibodies
WO2024094526A1 (en) 2022-11-02 2024-05-10 Ecole Polytechnique Federale De Lausanne (Epfl) 6-diazo-5-oxo-l-norleucine prodrugs
WO2024102730A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and nanoparticle compositions for delivering polynucleotides
WO2024102762A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
TW202440920A (zh) 2022-12-02 2024-10-16 大陸商上海舶望製藥有限公司 雙環脫鹼基核酸類似物以及由它們製備的寡聚化合物
WO2024129982A2 (en) 2022-12-15 2024-06-20 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2024205657A2 (en) 2023-03-29 2024-10-03 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
WO2024233308A2 (en) 2023-05-05 2024-11-14 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2024263649A1 (en) 2023-06-19 2024-12-26 Yale University Methods and compositions for enrichment and sequencing of expansion-specific rna transcripts
WO2025007148A1 (en) 2023-06-30 2025-01-02 Orna Therapeutics, Inc. Polymer lipid nanoparticle compositions for delivering circular polynucleotides
WO2025021993A1 (en) 2023-07-27 2025-01-30 Omnilinx Therapeutics Ag Endocytic and scavenger receptor-targeting chimeric proteins and uses thereof
WO2025029769A1 (en) 2023-07-31 2025-02-06 Eli Lilly And Company Solid forms of a kv1.3 potassium shaker channel blockers and method of using the same
US11957676B1 (en) 2023-08-07 2024-04-16 Zetagen Therapeutics, Inc. Controlled release formulation and minimally invasive method of administration to locally treat cancer
WO2025049690A1 (en) 2023-08-29 2025-03-06 Orna Therapeutics, Inc. Circular polyethylene glycol lipids
WO2025052303A1 (en) 2023-09-08 2025-03-13 Beigene Switzerland Gmbh Circular rna and preparation methods thereof
EP4537907A1 (en) 2023-10-10 2025-04-16 Enthera S.r.l. Cd248 inhibitors and uses thereof
WO2025097000A1 (en) 2023-11-01 2025-05-08 Yale University Antibody-based methods for treating polycystic kidney disease
WO2025117969A1 (en) 2023-12-01 2025-06-05 Orna Therapeutics, Inc. Process for manufacturing lipid nanoparticles

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2738303A (en) * 1952-07-18 1956-03-13 Smith Kline French Lab Sympathomimetic preparation
US3823228A (en) * 1971-09-29 1974-07-09 Univ Illinois Tge virus vaccine
CH594444A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1972-12-04 1978-01-13 Gerd Birrenbach
FR2287216A1 (fr) * 1974-10-09 1976-05-07 Narcisse Guy Nouvelle forme galenique d'administration de medicaments et medicaments prepares sous cette nouvelle forme
DK143689C (da) * 1975-03-20 1982-03-15 J Kreuter Fremgangsmaade til fremstilling af en adsorberet vaccine
DE2702952A1 (de) * 1976-02-04 1977-08-11 Medichemie Ag Kreislaufregulierendes, oral anzuwendendes arzneimittel
US4291016A (en) * 1976-07-27 1981-09-22 Sandoz Ltd. Enteric coated mixture of 4-(2-hydroxy-3-isopropylamino-propoxy) indole and sodium lauryl sulphate
US4123519A (en) * 1976-08-17 1978-10-31 Philips Roxane, Inc. Injectable contraceptive vaccine and method
FR2408345A1 (fr) * 1976-11-30 1979-06-08 Besins Jean Louis Nouvelle composition a action anti-conceptionnelle
JPS58318B2 (ja) * 1977-07-11 1983-01-06 住友化学工業株式会社 制癌性物質の製造方法
US4166800A (en) * 1977-08-25 1979-09-04 Sandoz, Inc. Processes for preparation of microspheres
US4152415A (en) * 1978-08-18 1979-05-01 Iowa State University Research Foundation, Inc. Method of increasing the effectiveness of oral vaccination for swine dysentery
US4152413A (en) * 1978-08-18 1979-05-01 Chromalloy American Corporation Oral vaccine for swine dysentery and method of use
US4152414A (en) * 1978-08-18 1979-05-01 Iowa State University Research Foundation, Inc. Combination vaccine for swine dysentery and method of use
US4203968A (en) * 1978-08-18 1980-05-20 Iowa State University Research Foundation, Inc. Combination vaccine for swine dysentery and method of use
US4732763A (en) * 1978-10-17 1988-03-22 Stolle Research And Development Corporation Active/passive immunization of the internal female reproductive organs
US4585651A (en) * 1978-10-17 1986-04-29 Stolle Research & Development Corporation Active/passive immunization of the internal female reproductive organs
US4309406A (en) * 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4298002A (en) * 1979-09-10 1981-11-03 National Patent Development Corporation Porous hydrophilic materials, chambers therefrom, and devices comprising such chambers and biologically active tissue and methods of preparation
GB2058562B (en) * 1979-09-14 1983-11-30 Beecham Group Ltd Pharmaceutical compositions containing paracetamol and ascorbic acid
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
US4439199A (en) * 1980-02-19 1984-03-27 Alza Corporation Method for administering immunopotentiator
US4384975A (en) * 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4455142A (en) * 1980-07-07 1984-06-19 Alza Corporation Method of coadministering an antigen and an immunopotentiator
JPS5719660A (en) * 1980-07-09 1982-02-01 Fuji Photo Film Co Ltd Microcapsule for immune reaction
JPS5719662A (en) * 1980-07-09 1982-02-01 Fuji Photo Film Co Ltd Preparation of microcapsule reagent for immune reaction
US4326524A (en) * 1980-09-30 1982-04-27 Minnesota Mining And Manufacturing Company Solid dose ballistic projectile
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4657756A (en) * 1980-11-17 1987-04-14 Schering Aktiengesellschaft Microbubble precursors and apparatus for their production and use
US4349530A (en) * 1980-12-11 1982-09-14 The Ohio State University Implants, microbeads, microcapsules, preparation thereof and method of administering a biologically-active substance to an animal
ZA822995B (en) * 1981-05-21 1983-12-28 Wyeth John & Brother Ltd Slow release pharmaceutical composition
IT1220979B (it) * 1981-06-04 1990-06-21 Lofarma Farma Lab Capsule contenenti un allergene e procedimento per la loro preparazione
IL63220A (en) * 1981-07-01 1985-09-29 Yeda Res & Dev Process for production of polyacrolein microspheres
SE8204244L (sv) * 1982-07-09 1984-01-10 Ulf Schroder Kristalliserad kolhydratsmatris for biologiskt aktiva substanser
US4428926A (en) * 1981-12-18 1984-01-31 Key Pharmaceuticals, Inc. Sustained release propranolol system
US4428925A (en) * 1981-12-18 1984-01-31 Key Pharmaceuticals, Inc. Sustained release glycerol trinitrate
US4479911A (en) * 1982-01-28 1984-10-30 Sandoz, Inc. Process for preparation of microspheres and modification of release rate of core material
US4434153A (en) * 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US4484923A (en) * 1982-03-25 1984-11-27 Alza Corporation Method for administering immunopotentiator
EP0092918B1 (en) * 1982-04-22 1988-10-19 Imperial Chemical Industries Plc Continuous release formulations
JPS58209984A (ja) * 1982-05-28 1983-12-07 Japan Synthetic Rubber Co Ltd 粒子状重合体よりなる担体
US4542025A (en) * 1982-07-29 1985-09-17 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4525339A (en) * 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
AU567155B2 (en) * 1983-04-15 1987-11-12 Damon Biotech Inc. Capsules for releasing core material at constant rate
US4690682A (en) * 1983-04-15 1987-09-01 Damon Biotech, Inc. Sustained release
US4608278A (en) * 1983-06-22 1986-08-26 The Ohio State University Research Foundation Small particule formation and encapsulation
IL72106A (en) * 1983-06-22 1988-02-29 Univ Ohio State Res Found Process for microencapsulating a weakly acidic or basic organic compound
GB2160312B (en) * 1984-04-13 1987-09-16 South African Inventions Adjuvant for immunisation
US4764359A (en) * 1984-05-25 1988-08-16 Lemelson Jerome H Drug compositions and their use in treating human or other mammalian patients
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
US4681722A (en) * 1985-10-07 1987-07-21 Owens-Corning Fiberglas Corporation Method of making a lineal structural member
WO1987003197A1 (en) * 1985-11-29 1987-06-04 Fisons Plc Pharmaceutical composition including sodium cromoglycate
WO1987006129A1 (en) * 1986-04-10 1987-10-22 Daratech Pty. Ltd. Vaccine and implant
NZ221411A (en) * 1986-08-11 1989-10-27 Innovata Biomed Ltd Pharmaceutical compositions containing microcapsules and a surfactant
WO1988001213A1 (en) * 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
IL84167A (en) * 1986-10-24 1991-04-15 Southern Res Inst Oral delivery of bioactive agents to and through the peyer's patch by use of microencapsulation
GB8712176D0 (en) * 1987-05-22 1987-06-24 Cosmas Damian Ltd Drug delivery system

Also Published As

Publication number Publication date
IE83868B1 (en) 2005-04-20
ZA892103B (en) 1990-01-31
DK175851B1 (da) 2005-04-04
RU2127118C1 (ru) 1999-03-10
US5075109A (en) 1991-12-24
EP0706792B1 (en) 2003-11-12
CN1211080C (zh) 2005-07-20
EP0333523A2 (en) 1989-09-20
GR3020569T3 (en) 1996-10-31
DE68929499D1 (de) 2003-12-18
NZ228376A (en) 1992-05-26
AU633483B2 (en) 1993-02-04
RU2005104392A (ru) 2006-07-27
CN1308937A (zh) 2001-08-22
IL89602A0 (en) 1989-09-10
JPH03503892A (ja) 1991-08-29
EP1181929A2 (en) 2002-02-27
CN1070697C (zh) 2001-09-12
AU3343389A (en) 1989-10-05
DE68929499T2 (de) 2004-09-16
WO1989008449A1 (en) 1989-09-21
KR900700084A (ko) 1990-08-11
KR0126823B1 (ko) 1998-04-01
IN169330B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1991-09-28
CA1340692C (en) 1999-08-03
ATE140386T1 (de) 1996-08-15
HK38897A (en) 1997-04-04
RU2250102C2 (ru) 2005-04-20
ES2088890T3 (es) 1996-10-01
ATE253901T1 (de) 2003-11-15
DK222490D0 (da) 1990-09-17
DE68926828D1 (de) 1996-08-22
EP0333523A3 (en) 1990-01-31
JP2521827B2 (ja) 1996-08-07
IL89602A (en) 1993-07-08
EP1181929A3 (en) 2003-04-23
DE68926828T2 (de) 1997-01-09
EP0706792A1 (en) 1996-04-17
EP0333523B1 (en) 1996-07-17
DK222490A (da) 1990-11-16
CN1043442A (zh) 1990-07-04
IE960647L (en) 1989-09-18

Similar Documents

Publication Publication Date Title
ES2210268T3 (es) Procedimiento para potenciar respuestas inmunes y composiciones correspondientes.
US5853763A (en) Method for delivering bioactive agents into and through the mucosally-associated lymphoid tissue and controlling their release
IE19960647A1 (en) Method of potentiating an immune response and compositions therefor
Eldridge et al. Biodegradable microspheres: vaccine delivery system for oral immunization
ES2243497T3 (es) Composicion de vacuna, procedimiento de preparacion de la misma y procedimiento para vacunacion de vertebrados.
Challacombe et al. Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen
AU607439B2 (en) Method and formulation for orally administering bioactive agents to and through the peyer's patch
ES2311451T3 (es) Carbohidratos policationicos como immuestimulantes en vacunas.
Hanes et al. Polymer microspheres for vaccine delivery
ES2234152T3 (es) Vectores de antigenos en forma de vesiculas multilamelares.
DK175961B1 (da) Anvendelse af biokompatible mikrokapsler og sammensætning indeholdende biokompatible mikrokapsler til potensering af et immunrespons
NZ241320A (en) Delivery of bioactive agent to the mucosally associated lymphoreticular tissues of non-human animals
JP4944335B2 (ja) 粘膜表面へ投与するための医薬組成物
WO2003059383A1 (es) COMPOSICÍON DE VACUNA FRENTE A LA BRUCELOSIS QUE COMPRENDE MICROPARTÍCULAS DE POLI(ϵ-CAPROLACTONA) COMO ADYUVANTE